Treatment of type 2 diabetes with saxagliptin: A pharmacoeconomic evaluation in Argentina

Health Economics Review

Volumn 3, Issue 1, 2013, Pages 1-9

  Elgart, Jorge F ^a   Caporale, Joaquin E ^a   Gonzalez, Lorena ^a   Aiello, Eleonora ^b   Waschbusch, Maximiliano ^b   Gagliardino, Juan J ^a  

^a University of La Plata CONICET   (Argentina)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Argentina; Cost effectiveness analysis; DPP 4 inhibitors; Latin America; Pharmacoeconomics; Saxagliptin; Type 2 diabetes treatment

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SULFONYLUREA; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AMPUTATION; ARGENTINA; ARTICLE; BLINDNESS; BODY MASS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG UTILIZATION; ECONOMIC EVALUATION; FEMALE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIDE EFFECT;

EID: 84971219454     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-3-11     Document Type: Article

References (46)

1. International Diabetes Federation: IDF Diabetes Atlas. Fourth Editionth edition. Brussels; 2009. Available at: http://www.eatlas.idf.org. Accessed on May 4, 2011.
2. Ferrante D, Linetzky B, Konfino J, King A, Virgolini M, Laspiur S: Encuesta Nacional de Factores de Riesgo 2009: evolución de la epidemia de enfermedades crónicas no transmisibles en Argentina. Estudio de corte transversal. Rev Argent Salud Pública 2011, 2:34-41.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
4. Ong KL, Cheung BMY, Wong LYF, Wat NM, Tan KC, Lam KS: Prevalence, treatment and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008, 18:222-229.
5. Chan JC, Gagliardino JJ, Baik SH, Chantelot JM, Ferreira SR, Hancu N, Ilkova H, Ramachandran A, Aschner P, IDMPS Investigators: Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes Care 2009, 32:227-233.
6. Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P: Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract 2009, 63:997-1007.
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: American Diabetes Association; European Association for Study of Diabetes: medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care 2009, 32:193-203.
8. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131:281-303.
9. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002, 287:360-372.
10. Charpentier G: Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 2002, 18:S70-S76.
11. Riddle MC: Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005, 34:77-98.
12. American Association of Clinical Endocrinologists: Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(S1):3-68.
13. Barnard K, Cox ME, Green JB: Clinical utility of fixed combinations of sitagliptin-metformin in treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2010, 3:363-372.
14. Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H: Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008, 10(Suppl 1):43-55.
15. Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 2007, 30:1638-1646.
16. McEwan P, Peters JR, Bergenheim K, Currie CJ: Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr Med Res Opin 2006, 22:121-129.
17. McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP: Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics 2010, 28:665-674.
18. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR: UK Prospective Diabetes Study (UKDPS) Group: A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004, 47:1747-1759.
19. Ministerio de Salud de la Nación: Guía de Práctica Clínica Nacional sobre Prevención. Buenos Aires: Diagnóstico y Tratamiento de la Diabetes Mellitus Tipo 2 Para el Primer Nivel de Atención; 2009. Available from: http://www.msal. gov.ar/ent/images/stories/equipos-salud/pdf/gpc_prevencion-diagnostico-tratamiento-diabetes-mellitus-tipo-2.pdf; accessed on January 10, 2013.
20. Sociedad Argentina de Diabetes: Guía del tratamiento de la diabetes mellitus tipo 2. Rev Soc Arg de Diabetes 2010, 44:358-384.
21. National Institute for Health and Clinical Excellence: Clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes (partial update). NICE; 2009. Available from: http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf; accessed on 20 December 2009.
22. Gagliardino JJ, En representación del Grupo IDMPS: Resultados del International Diabetes Management Practices Study (IDMPS) en la Argentina en DMT2 [abstract]. Rev Soc Argent de. Diabetes 2008, 42:132.
23. Gagliardino JJ, On behalf of the IDMPS Group: Results of International Diabetes Management Practices Study (IDMPS) in Argentina. In 29th World Congress of Internal Medicine. Buenos Aires: Abstracts Book; 2008:50. Available from: http://www.smiba.org.ar/isim2008/Libro-Final-trab-pres.pdf.
24. Gagliardino JJ, On behalf of the IDMPS Group: International Diabetes Management Practices Study (IDMPS): Results in T2DM. In 29th World Congress of Internal Medicine. Buenos Aires: Abstracts Book; 2008:63. Available from: http://www.smiba.org.ar/isim2008/Libro-Final-trab-pres.pdf.
25. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I: D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010, 64:1619-1631.
26. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853.
27. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG: Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
28. Ahrén B, Foley JE, Ferrannini E, Matthews DR, Zinman B, Dejager S, Fonseca VA: Changes in prandial glucagon levels after 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy. Diabetes Care 2010, 33:730-732.
29. White J: Efficacy and safety of incretin based therapies: clinical trial data. J Am Pharm Assoc 2009, 49(Suppl 1):S30-S40. Review.
30. Madsbad S: Lliraglutide effect and action in diabetes (LEAD TM) Trial. Expert Rev Endocrinol Metab 2009, 4:119-129.
31. Health Survey for England: Health Survey for England 2003 trends. Available from: http://webarchive.nationalarchives.gov.uk/20130107105354/http:// www.dh.gov.uk/en/PublicationsAndStatistics/PublishedSurvey/ HealthSurveyForEngland/HealthSurveyResults/DH_4098913; accessed on 20 December 2009.
32. Clarke P, Gray A, Legood R, Briggs A, Holman R: The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003, 20:442-450.
33. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S: The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005, 8:581-590.
34. Sherwyn L, Schwartz MD: Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2010, 8:405-418.
35. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
36. Weisbrod BA: The Health Care Quadrilemma: an essay on technological change, insurance, quality of care and cost containment. J Econ Literat 1991, 29:523-532.
37. Burner ST, Waldo DR: National health expenditure projections,1994-2005. Health Care Financ Rev 1995, 16:221-242.
38. Eddy DM: Benefit language: criteria that will improve quality while reducing costs. JAMA 1996, 275:650-657.
39. Eddy DM: Investigational treatments: how strict should we be? JAMA 1997, 278:179-185.
40. Canadian Task Force on the Periodic Health Examination: The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979, 121:1193-1254.
41. U.S. Preventive Services Task Force: Guide to Clinical Preventive Services. 2nd edition. Baltimore: Williams and Wilkins; 1996.
42. Sachs JD: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
43. Baltussen RMPM, Adam T, Tan-Torres Edejer T, Hutubessy RCW, Acharya A, Evans DB, Murray CJL: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
44. World Development Indicators database: World Bank. 2011. Available from: http://data.worldbank.org/. Accessed on April 15.
45. Granström O, Bergenheim K, McEwan P, Sennfält K, Henriksson M: Cost-effectiveness of saxagliptin (Onglyza(®)) in type 2 diabetes in Sweden. Prim Care Diabetes 2012, 6:127-136.
46. Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P: Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012, 32:189-202.